메뉴 건너뛰기




Volumn 18, Issue 11, 2016, Pages 1072-1080

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

Author keywords

basal insulin; glycaemic control; hypoglycaemia; randomized trial; type 2 diabetes

Indexed keywords

AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; TRIACYLGLYCEROL; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; MACROGOL DERIVATIVE;

EID: 84990211837     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12696     Document Type: Article
Times cited : (20)

References (36)
  • 1
    • 84901445280 scopus 로고    scopus 로고
    • Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment
    • Halban PA, Polonsky KS, Bowden DW et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751–1758.
    • (2014) Diabetes Care , vol.37 , pp. 1751-1758
    • Halban, P.A.1    Polonsky, K.S.2    Bowden, D.W.3
  • 2
    • 0028817815 scopus 로고
    • U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease
    • U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–1258.
    • (1995) Diabetes , vol.44 , pp. 1249-1258
  • 3
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
    • (2015) Diabetes Care , vol.38 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 4
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
    • UK Prospective Diabetes Study (UKPDS) Group, Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 7
    • 84871937855 scopus 로고    scopus 로고
    • Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
    • Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175–184.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 175-184
    • Ratner, R.E.1    Gough, S.C.2    Mathieu, C.3
  • 8
    • 84939572199 scopus 로고    scopus 로고
    • Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
    • Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17: 859–867.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 859-867
    • Ritzel, R.1    Roussel, R.2    Bolli, G.B.3
  • 9
    • 84874415108 scopus 로고    scopus 로고
    • LY2605541: leveraging hydrodynamic size to develop a novel basal insulin
    • Hansen RJ, Cutler GB, Vick A et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 2012; 61(Suppl. 1): A228.
    • (2012) Diabetes , vol.61 , pp. A228
    • Hansen, R.J.1    Cutler, G.B.2    Vick, A.3
  • 10
    • 84900825441 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
    • Sinha VP, Choi SL, Soon DK et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54: 792–799.
    • (2014) J Clin Pharmacol , vol.54 , pp. 792-799
    • Sinha, V.P.1    Choi, S.L.2    Soon, D.K.3
  • 11
    • 84895133323 scopus 로고    scopus 로고
    • Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
    • Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344–350.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 344-350
    • Sinha, V.P.1    Howey, D.C.2    Choi, S.L.3    Mace, K.F.4    Heise, T.5
  • 12
    • 84990219047 scopus 로고    scopus 로고
    • Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM)
    • (Suppl. 1A)
    • Mudaliar S, Henry RR, Ciaraldi TP et al. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM). Diabetes 2015; 64(Suppl. 1A): LB22–LB23.
    • (2015) Diabetes , vol.64 , pp. LB22-LB23
    • Mudaliar, S.1    Henry, R.R.2    Ciaraldi, T.P.3
  • 13
    • 84906691684 scopus 로고    scopus 로고
    • Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects
    • Henry RR, Mudaliar S, Ciaraldi TP et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014; 37: 2609–2615.
    • (2014) Diabetes Care , vol.37 , pp. 2609-2615
    • Henry, R.R.1    Mudaliar, S.2    Ciaraldi, T.P.3
  • 14
    • 84990242710 scopus 로고    scopus 로고
    • Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial
    • May 12 [Epub ahead of print]
    • Morrow LA, Hompesch M, Jacober SJ, Choi SL, Qu Y, Sinha VP. Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial. Diabetes Obes Metab 2016; May 12 [Epub ahead of print] doi:10.1111/dom.12691.
    • (2016) Diabetes Obes Metab
    • Morrow, L.A.1    Hompesch, M.2    Jacober, S.J.3    Choi, S.L.4    Qu, Y.5    Sinha, V.P.6
  • 15
    • 84893090167 scopus 로고    scopus 로고
    • Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism
    • Moore MC, Smith MS, Sinha VP et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014; 63: 494–504.
    • (2014) Diabetes , vol.63 , pp. 494-504
    • Moore, M.C.1    Smith, M.S.2    Sinha, V.P.3
  • 16
    • 0031851293 scopus 로고    scopus 로고
    • Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
    • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
    • (1998) Diabet Med , vol.15 , pp. 539-553
    • Alberti, K.G.1    Zimmet, P.Z.2
  • 17
    • 84874413470 scopus 로고    scopus 로고
    • Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study
    • Rosenstock J, Bergenstal RM, Blevins TC et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522–528.
    • (2013) Diabetes Care , vol.36 , pp. 522-528
    • Rosenstock, J.1    Bergenstal, R.M.2    Blevins, T.C.3
  • 18
    • 84938561571 scopus 로고    scopus 로고
    • Performance of an electronic diary system for intensive insulin management in Global Diabetes Clinical Trials
    • Bastyr EJ III, Zhang S, Mou J et al. Performance of an electronic diary system for intensive insulin management in Global Diabetes Clinical Trials. Diabetes Technol Ther 2015; 17: 571–579.
    • (2015) Diabetes Technol Ther , vol.17 , pp. 571-579
    • Bastyr, E.J.1    Zhang, S.2    Mou, J.3
  • 19
    • 54549114505 scopus 로고    scopus 로고
    • General multistage gatekeeping procedures
    • Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008; 50: 667–677.
    • (2008) Biom J , vol.50 , pp. 667-677
    • Dmitrienko, A.1    Tamhane, A.C.2    Wiens, B.L.3
  • 20
    • 84921676349 scopus 로고    scopus 로고
    • Estimation of group means when adjusting for covariates in generalized linear models
    • Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat 2015; 14: 56–62.
    • (2015) Pharm Stat , vol.14 , pp. 56-62
    • Qu, Y.1    Luo, J.2
  • 21
    • 84990226055 scopus 로고    scopus 로고
    • Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
    • [Submitted Paper]
    • Davies MJ, Russel-Jones D, Selam J-L et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab 2016 [Submitted Paper].
    • (2016) Diabetes Obes Metab
    • Davies, M.J.1    Russel-Jones, D.2    Selam, J.-L.3
  • 22
    • 84990211099 scopus 로고    scopus 로고
    • A Randomized Clinical Trial of Basal Insulin Peglispro versus NPH in Insulin-Naïve Patients with Type 2 Diabetes: IMAGINE 6
    • [Submitted Paper]
    • Grunberger G, Chen L, Rodríguez Á et al. A Randomized Clinical Trial of Basal Insulin Peglispro versus NPH in Insulin-Naïve Patients with Type 2 Diabetes: IMAGINE 6. Diabetes Obes Metab 2016 [Submitted Paper].
    • (2016) Diabetes Obes Metab
    • Grunberger, G.1    Chen, L.2    Rodríguez, Á.3
  • 23
    • 84990202423 scopus 로고    scopus 로고
    • A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1
    • [Submitted Paper]
    • Garg SK, Dreyer M, Jinnouchi H et al. A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1. Diabetes Obes Metab 2016 [Submitted Paper].
    • (2016) Diabetes Obes Metab
    • Garg, S.K.1    Dreyer, M.2    Jinnouchi, H.3
  • 24
    • 84962129833 scopus 로고    scopus 로고
    • Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with Type 2 diabetes previously treated with basal insulin: IMAGINE 5
    • Buse JB, Rodbard HW, Trescoli Serrano C et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with Type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care 2016; 39: 92–100.
    • (2016) Diabetes Care , vol.39 , pp. 92-100
    • Buse, J.B.1    Rodbard, H.W.2    Trescoli Serrano, C.3
  • 25
    • 84990179399 scopus 로고    scopus 로고
    • A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
    • Bergenstal RM, Lunt H, Franek E et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab 2016 doi: 10.1111/dom.12698.
    • (2016) Diabetes Obes Metab
    • Bergenstal, R.M.1    Lunt, H.2    Franek, E.3
  • 26
    • 84868131614 scopus 로고    scopus 로고
    • A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
    • Bergenstal RM, Rosenstock J, Arakaki RF et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140–2147.
    • (2012) Diabetes Care , vol.35 , pp. 2140-2147
    • Bergenstal, R.M.1    Rosenstock, J.2    Arakaki, R.F.3
  • 27
    • 84990175032 scopus 로고    scopus 로고
    • Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials
    • [Submitted Paper]
    • Ginsberg H, Cariou B, Orchard T et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab 2016 [Submitted Paper].
    • (2016) Diabetes Obes Metab
    • Ginsberg, H.1    Cariou, B.2    Orchard, T.3
  • 28
    • 84858110025 scopus 로고    scopus 로고
    • Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis
    • Chaudhuri A, Rosenstock J, DiGenio A et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012; 28: 258–267.
    • (2012) Diabetes Metab Res Rev , vol.28 , pp. 258-267
    • Chaudhuri, A.1    Rosenstock, J.2    DiGenio, A.3
  • 29
    • 33748522381 scopus 로고    scopus 로고
    • A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study
    • Gerstein HC, Yale JF, Harris SB et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 2006; 23: 736–742.
    • (2006) Diabet Med , vol.23 , pp. 736-742
    • Gerstein, H.C.1    Yale, J.F.2    Harris, S.B.3
  • 30
    • 33244479164 scopus 로고    scopus 로고
    • Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
    • Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–451.
    • (2006) Diabetologia , vol.49 , pp. 442-451
    • Yki-Jarvinen, H.1    Kauppinen-Makelin, R.2    Tiikkainen, M.3
  • 31
    • 84969543105 scopus 로고    scopus 로고
    • Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
    • Hoogwerf BJ, Lincoff AM, Rodriguez A et al. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol 2016; 15: 78.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 78
    • Hoogwerf, B.J.1    Lincoff, A.M.2    Rodriguez, A.3
  • 32
    • 18244382304 scopus 로고    scopus 로고
    • Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
    • Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351.
    • (2005) J Clin Invest , vol.115 , pp. 1343-1351
    • Donnelly, K.L.1    Smith, C.I.2    Schwarzenberg, S.J.3
  • 33
    • 84921818351 scopus 로고    scopus 로고
    • Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
    • Vatner DF, Majumdar SK, Kumashiro N et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci 2015; 112: 1143–1148.
    • (2015) Proc Natl Acad Sci , vol.112 , pp. 1143-1148
    • Vatner, D.F.1    Majumdar, S.K.2    Kumashiro, N.3
  • 34
    • 84878248928 scopus 로고    scopus 로고
    • Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
    • Mashhood A, Railkar R, Yokoo T et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging 2013; 37: 1359–1370.
    • (2013) J Magn Reson Imaging , vol.37 , pp. 1359-1370
    • Mashhood, A.1    Railkar, R.2    Yokoo, T.3
  • 35
  • 36
    • 34247593406 scopus 로고    scopus 로고
    • Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
    • Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21: 137–142.
    • (2007) J Diabetes Complications , vol.21 , pp. 137-142
    • Lingvay, I.1    Raskin, P.2    Szczepaniak, L.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.